




Substitute for form 1449B/PTO				<b>Compl t if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				RECEIVED	
Date Submitted: July 24, 2002				AUG 14 2002	
(use as many sheets as necessary)				TECH CENTER 1600/200	
Sheet	1	of	3	Attorney Docket Number	038602-1082

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A14	Breier et al., "Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation," <u>Development</u> 114:521-532, 1992.	
	A15	Conn et al., "Purification of a Glycoprotein Vascular Endothelial Cell Mitogen From a Rat Glioma-derived Cell Line," <u>Proc. Natl. Acad. Sci. USA</u> 87:1323-1327, 1990.	
	A16	Connolly et al., "Human Vascular Permeability Factor. Isolation from U937 Cells," <u>The Journal of Biological Chemistry</u> , Vol. 264, No. 33, p.20021, (25 November 1989).	

Examiner Signature	J. Spector	Date Considered	11/13/02
-----------------------	------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper #9

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: July 24, 2002

(use as many sheets as necessary)

Sheet 2 of 3

*Compl t if Known***RECEIVED**

Application Number	09/766,678
Filing Date	01/23/2001
First Named Inventor	Axel ULLRICH et al.
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	038602-1082

AUG 14 2002

TECH CENTER 1600/1900

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A17	De Vries et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991, 1992.	
	A18	Ferrara et al., "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochem. Biophys. Res. Comm.</u> 161:851-858, 1989.	
	A19	Ferrara et al., "The Vascular Endothelial Growth Factor Family of Polypeptides," <u>J. Cell Biochem.</u> 47:211-218, 1991.	
	A20	Gospodarowicz et al., "Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells," <u>Proc. Natl. Acad. Sci. USA</u> 86:7311-7315, 1989.	
	A21	Kashles et al., "A Dominant Negative Mutation Suppresses the Function of Normal Epidermal Growth Factor Receptors by Heterodimerization," <u>Mol. Cell. Biol.</u> 11:1454-1463, 1991.	
	A22	Klagsburn et al., "Regulators of Angiogenesis" <u>Annu. Rev. Physiol.</u> 53:217-39, 1991.	
	A23	Leung et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <u>Science</u> 246:1306-1309, 1989.	
	A24	Li et al., "Monoclonal antibodies to recombinant human vascular endothelial growth factor (rHuVEGF)," <u>Journal of Cellular Biochemistry</u> , vol. Suppl., no. 15F, p.251, (1991).	
	A25	Livneh et al., "Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells," <u>J. Biol. Chem.</u> 261(27):12490-12497, 1986.	
	A26	Maglione et al., "Isolation of Human Placental cDNA Coding For a Protein Related to the Vascular Permeability Factor," <u>Proc. Natl. Acad. Sci. USA</u> 88:9267-9271, 1991.	
	A27	Matthews et al., "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to c-kit," <u>Proc. Natl. Acad. Sci. USA</u> 88:9026-9030, 1991.	
	A28	McCormick, "Human gene therapy: The first round," <u>Biotechnology</u> 3(8):689-693, 1985.	
	A29	McMahon et al., "Protein kinase inhibitors: structural determinants for target specificity," <u>Current Opinions in Drug Discovery and Development</u> 1(2):131-146, 1998.	
	A30	Millauer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," <u>Cell</u> 72:835-846, 1993.	
	A31	Mitchell et al., "Recombinant Expression and Characterization of the 121 Amino Acid Form of Vascular Endothelial Growth Factor (VEGF)," <u>J. Cell. Biochem., Keystone Symposia on Molecular and Cellular Biology</u> , Supplement 15C, Excerpt G207, 1991.	

Examiner Signature

Date Considered

11/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

AUG 12 2002

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1615, TRADES TO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: July 24, 2002

(use as many sheets as necessary)

Sheet 3 of 3

**Complete if Known**

Application Number	09/766,678	RECEIVED
Filing Date	01/23/2001	AUG 14 2002
First Name Inv. ntor	Axel ULLRICH et al.	TECH CENTER 1600/900
Group Art Unit	1647	
Examiner Name	Lorraine Spector	
Attorney Docket Number	038602-1082	

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A32	Nicolas et al., "Retroviral Vectors," <u>Vectors</u> , Chapter 25, pp. 493-494, 1987.	
	A33	Orkin et al., "Report and Recommendations of the panel to assess the NIH investment in research on gene therapy", December 7, 1995.	
	A34	Plate et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," <u>Cancer Research</u> 53:5822-5827, 1993.	
	A35	Prywes et al., "Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization," <u>EMBO J.</u> 5(9):2179-2190, 1986.	
	A36	Risau et al., "Changes in the Vascular Extracellular Matrix During Embryonic Vasculogenesis and Angiogenesis," <u>Development Biology</u> 125:441-450, 1988.	
	A37	Sarzani et al., "A Novel Endothelial Tyrosine Kinase cDNA Homologous To Platelet-Derived Growth Factor Receptor cDNA" <u>Biochem. Biophys. Res. Comm.</u> 186:706-714, 1992.	
	A38	Spivak-Kroizman et al., "Heterodimerization of c-erbB2 With Different Epidermal Growth Factor Receptor Mutants Elicit Stimulatory or Inhibitory Responses," <u>J. Biol. Chem.</u> 267:8056-8063, 1992.	
	A39	Strawn et al., "Flk-1 as a Target for Tumor Growth Inhibition," <u>Cancer Research</u> 56:3540-3545, 1996.	
	A40	Tartaglia et al., <u>J. Biol. Chem.</u> 267(7), 4304-4307, March 5, 1992.	
	A41	Terman et al., "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," <u>Oncogene</u> 6:1677-1683, 1991.	
	A42	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," <u>Biochem. Biophys. Res. Comm.</u> 187:1579-1586, 1992.	
	A43	Traxler, "Tyrosine kinase inhibitors in cancer treatment (Part II)," <u>Exp. Opin. Ther. Patents</u> 8(12):1599-1625, 1998.	
	A44	Ueno et al., <u>J. Biol. Chem.</u> 267(3):1470-1476, January 25, 1992.	
	A45	Ueno et al., <u>Science</u> 252:844-848, May 10, 1991.	
↓	A46	Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity", <u>Cell</u> 61:203-212, 1990.	

Examiner Signature

Date Considered

11/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.